BRAF and melanoma: Vemurafenib (Zelboraf®) and dabrafenib (Tafinlar®) are ATP-competitive BRAF inhibitors (BRAFi) highly selective for the V600E-mutant, both approved for the treatment of metastatic melanoma.3–5 While approximately half of melanoma patients harboring this mutation respond to single agent therapy, the duration of response is typically less than a year.